Susan Spinasanta

Managing Medical Editor, Content Development
Vertical Health, LL
Cape Coral, FL

About Susan Spinasanta

Susan has 20 years of experience in medical editing and writing.  She is accomplished and knowledgeable in many areas of medicine, science, and technology.

Many of Susan's projects involve collaborating with experts—such as professionals in specific areas of medicine and/or key opinion leaders involved in improving patient lives.  A published author of hundreds of patient and consumer materials, the majority of her work benefits medical professionals.  Susan develops content for case studies, continuing medical education programs, video presentations, online resource centers, guidelines for patient care, and other content based projects.

Susan is an active member of the American Medical Writers Association (AMWA), American Thyroid Association, The Endocrine Society, and the North American Spine Society. In addition to these and other educational opportunities, she attends society meetings for medical professionals to broaden her knowledge of current healthcare standards and advances in patient care.

Articles Written by Susan Spinasanta

Role of Gene Expression Classification in Assessing Thyroid Nodules
EndocrineWeb spoke with Dr. Richard Kloos about the incidence of thyroid nodules and the role of gene expression classifiers. The interview was timely considering that during The Endocrine Society’s annual meeting the American Thyroid Association’s (ATA) preliminary guidelines regarding the management of thyroid nodules were announced.
Nexavar® (sorafenib) FDA-approved for Differentiated Thyroid Cancer
The FDA announced approval of Nexavar® tablets (sorafenib) for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma that is refractory to radioactive iodine treatment.
Addison’s Disease and Adrenal Insufficiency Overview
Addison’s disease, a rare disorder, develops when the adrenal glands do not produce enough of the hormone cortisol. Sometimes, the adrenal glands also don’t produce enough of the aldosterone hormone. Includes list of Addison’s disease symptoms.
FDA Adds New Warning to Labels of Saxagliptin and Alogliptin Products
The FDA added new warnings regarding an increased risk of hospitalization for heart failure to the drug labels for diabetes medications containing saxagliptin and alogliptin.
NCI-MATCH Precision Medicine Trial Will Begin Enrolling Patients in July
The National Cancer Institute (NCI)-supported precision medicine trial known as NCI-MATCH (Molecular Analysis for Therapy Choice) will begin enrollment in July 2015. The goal of the trial is to determine whether select cancer treatments are effective against specific molecular abnormalities, regardless of tumor type. Learn more about the trial and how patients can enroll.
American Association of Endocrine Surgeons 36th Annual Meeting
Register now for the American Association of Endocrine Surgeons (AAES) 36th Annual Meeting to be held May 17-19, 2015 in Nashville, TN. Here you can down the advance program.
Michelle Obama Takes on Obesity in America's Kids
Childhood obesity is rising, and it's a major risk factor for type 2 diabetes. First Lady Michelle Obama is actively addressing the childhood obesity problem with a national awareness program called Let's Move. Learn all about it in this article.
Parathryoid Hormone (NATPARA®) Approved by FDA to Help Control Hypocalcemia in Hypoparathryoidism
NATPARA® (NPS Pharmaceuticals, Inc., Bedminster NJ) for subcutaneous injection was approved by the US Food and Drug Administration on January 23, 2015.

Financial Disclosures for Susan Spinasanta

EndocrineWeb, a Vertical Health, LLC website, is committed to ensuring that the medical information it presents is accurate, balanced, objective, and trustworthy.

To help achieve this goal, EndocrineWeb requires all authors, editors, and reviewers to disclose any financial relationships or affiliations they have with companies whose products or services may be mentioned in the content they author, edit, or review.

The intent of this policy is to identify any perceived, potential, or real conflicts of interest so that readers can make their own judgments about the value of information being presented.

Author's Statement

I, the undersigned, declare that neither I nor members of my immediate family have a financial interests or affiliation with commercial companies whose products and / or services may be mentioned in the materials I have authored, edited or reviewed for presentation on Vertical Health, LLC’s websites.
There are no disclosures for this author
SHOW MAIN MENU
SHOW SUB MENU